R&D The value of unstructured data for drug companies Advancements in medical AI now allow pharmaceutical companies to leverage unstructured clinical data at scale.
Digital “Data is our currency” – with Ginkgo Datapoints’ John Andros... Successful use of AI is becoming a key differentiator for pharma companies.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.